LOS ANGELES, July 23, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report financial results for the second quarter 2015 on Thursday, August 6, 2015. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the second quarter 2015 financial results and provide a business update. The call will be hosted by Andrew Gengos, President and CEO.
(877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 79781010.
Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.
The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a Phase 2 trial of its lead product candidate, ICT-107, a dendritic cell (DC)-based immunotherapy targeting multiple stem cell-associated antigens for newly diagnosed glioblastoma patients. ImmunoCellular's pipeline also includes: ICT-121, a DC immunotherapy targeting the CD133 stem cell-antigen in recurrent glioblastoma; ICT-140, a DC immunotherapy targeting stem cell-associated antigens for ovarian cancer; and the Stem-to-T cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To learn more about ImmunoCellular, please visit www.imuc.com.
ImmunoCellular Therapeutics, Ltd.
SOURCE ImmunoCellular Therapeutics, Ltd.